QQ客服 官方微博 反馈留言

	Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
	Xiaohua Gu; Qiang Zhang; Yun-Bo Chu; Yi-Yang Zhao; Yan-Jun Zhang; David Kuo; Betty Su; Bin Wu
刊名	Lung Cancer
	2019
卷号	Vol.127页码:84-89
关键词	Afatinib EGFR mutation Cost-effectiveness Non-small cell lung cancer
ISSN号	0169-5002
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4608283
专题	湖南大学
作者单位	1.d Boston Healthcare, Shanghai, China a Department of Respiratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China 2.Boehringer Ingelheim Investment Co., Ltd., Shanghai, China 3.Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China 4.Department of Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
推荐引用方式 GB/T 7714	Xiaohua Gu,Qiang Zhang,Yun-Bo Chu,et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China[J]. Lung Cancer,2019,Vol.127:84-89.
APA	Xiaohua Gu.,Qiang Zhang.,Yun-Bo Chu.,Yi-Yang Zhao.,Yan-Jun Zhang.,...&Bin Wu.(2019).Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.Lung Cancer,Vol.127,84-89.
MLA	Xiaohua Gu,et al."Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China".Lung Cancer Vol.127(2019):84-89.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。